AVXL just meandering around here, a bit under 6. N
Post# of 1460
NTRP is a classic example of a botched data release of a study that was rushed. Had they let it run to the 6 months which would have been meaningful as a comparison to other Alzheimer's drugs, the stock price might be a very different story.
Impatience kills. I hope the company continues this study so we get some idea whether this pathway is a good one to pursue -- whether it's NTRP or some other company that does it.